• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • Latest
  • Videos
  • Series
  • E-Newsletters
    • Fat Tail Daily
    • James Cooper’s Mining Memo
    • The Daily Reckoning Australia
  • Categories
    • Commodities
    • Macro
    • Market Analysis
    • Small Caps
    • Technology
  • Investment Guides
  • Premium Services
  • Editors
  • About
  • Contact Us
  • Subscribe
Fat Tail Daily
Subscribe
  • Home
  • Latest
  • Videos
  • E-Newsletters
  • Premium Services
Latest ASX News

MGC Pharma Boasts Sales Milestone Sending Shares Higher (ASX:MXC)

Like 0

By Ryan Clarkson-Ledward, Tuesday, 20 October 2020

Is the pot stock boom back? That is the question that investors need to be asking themselves right now. As the sector both locally and abroad is seeing some noteworthy movement. Today, MGC Pharmaceuticals Ltd [ASX:MXC] was busy making their case...

Is the pot stock boom back?

That is the question that investors need to be asking themselves right now. As the sector both locally and abroad is seeing some noteworthy movement.

Today, MGC Pharmaceuticals Ltd [ASX:MXC] was busy making their case for the cannabis comeback with the MXC share price climbing on positive news. Noting significant sales growth over a consecutive period.

Granted, this is a company that is working off a tiny base. Both in terms of the volume sales and their key market.

That doesn’t make it any easier to ignore though, at least from an investing perspective…

Booming business

The big news is that MGC’s sales volume is up 65% from 30 June to date. With over 7,000 units of their cannabis-based medicine sold in the period.

Plus, in the past four weeks they’ve raked in over $225,000 worth of revenue. With each week beating the one before it. A strong sign of the momentum behind their booming sales.

And with strong demand from both Australia and Brazil, future sales are looking pretty damn good too. Not that MGC can afford to start taking things lightly just yet.

As CEO Roby Zomer notes:

‘It is increasingly brought to our attention that one of the major inhibiting factors for patient access to medicinal cannabis in Australia, and globally, is the high price point that comes with high-quality medications that are not covered by insurance.

‘We are constantly streamlining our operations in order to lower our overall cost base, to ensure we can meet our obligation to increase patient access to affordable, high-quality medicinal cannabis products. We are seeing the results of this strategy through the increase in patient demand and sales volume.’

So, in other words, Zomer believes that lower costs may be able to give MGC an advantage. Allowing his company to price their products at a much more tolerable range.

Whatever he’s doing, it certainly seems to be working.

The only question now is, will they be able to sustain this growth?

Budding enterprise

One thing is for sure, cannabis is a hot sector right now.

The possibility of a democratic election win and subsequent decriminalisation of cannabis is a real possibility. With Kamala Harris stating that they do plan to push this agenda if her party wins.

For that reason, a lot of speculation surrounding pot stocks is beginning to pick up.

Investors should be taking notice of this fact and keeping it in mind. Because this might truly be the start of another pot stock boom.

Time will tell…

Regards,

Ryan Clarkson-Ledward,
For Money Morning

PS: For more cutting-edge small-caps, check out one of our new reports. A detail looked at companies pioneering new tech trends. Get your free copy, right here.

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Ryan Clarkson-Ledward

Ryan’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • Iran is bad, but AI stock rebrands might be worse
    By Lachlann Tierney

    The Aussie budget is grim, but global markets have a far bigger fish to fry. There have been 33 ‘AI company’ rebrands, US$8.7 billion in ETF inflows, and the market is smelling a whiff of 1999.

  • At what point does populist politics become a problem for investors?
    By Nick Hubble

    Remember that famous billboard ad by Manhattan Mini Storage? ‘The French aristocracy didn’t see it coming either.’ Well, a socialist is the mayor of New York today…

  • Budget Watch: We’re all George Costanza now
    By Lachlann Tierney

    Australia's budget is coming on Tuesday, 12 May, and it will likely make investors feel like George Costanza. Maybe investors will embrace pure nihilism and swing for the fences even more?

Primary Sidebar

Latest Articles

  • Iran is bad, but AI stock rebrands might be worse
  • At what point does populist politics become a problem for investors?
  • Budget Watch: We’re all George Costanza now
  • The Australian Economy’s Getting a Pay Rise, but it’s Still Depressed
  • The Walls are Closing in on Trump

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2026 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988